Introduction {#s1}
============

Carcinoembryonic antigen (CEA) is a glycoprotein involved in cell adhesion, is used as a tumor marker in a variety of tumors, and plays an important role in the prognosis of non-small cell lung cancer (NSCLC) patients \[[@R01]\].

Previous investigations reported that the serum concentration of serum prostate-specific antigen (PSA) level in obese patients with prostate cancer is lower compared with that in non-obese subjects \[[@R04]\]. These investigations showed that a lower serum PSA level was associated with increasing body mass index (BMI) \[[@R04]\]. The reason for this phenomenon has been considered as a hemodilution effect due to the larger vascular volume of obese patients \[[@R04]\]. On the other hand, others found no significant association between BMI and PSA \[[@R07], [@R08]\]. With regard to CEA, the relation between serum CEA concentration and obesity was also examined in colorectal cancer patients \[[@R09], [@R10]\]. However, the number of available studies investigating the association between BMI and serum CEA concentration is limited \[[@R09]\]. Despite the abundant literature on serum CEA concentration in NSCLC \[[@R01]\], there are no previous investigations on the hemodilution effect on serum CEA concentration in obese NSCLC patients. Therefore, in the present study, we investigated the association between BMI and serum CEA concentration in resected NSCLC patients.

Patients and Methods {#s2}
====================

This retrospective study had institutional review board approval, and the need to obtain patient consent was waived. Consecutive NSCLC patients who examined preoperative serum CEA concentration and underwent surgery from 2008 to 2013 in our hospital were enrolled into the present retrospective study. The collected records of 381 consecutive NSCLC patients were reviewed retrospectively.

The preoperative serum CEA concentration (ng/mL) was measured by enzyme immunoassay in a single laboratory at our hospital. The preoperative BMI was calculated as weight in kilograms divided by height in meters squared. According to the previous investigation \[[@R10]\], the following category was used: low BMI group (BMI \< 18.5 kg/m^2^), normal BMI group (BMI = 18.5 - 24.0 kg/m^2^) and high BMI group (BMI \> 24.0 kg/m^2^). Two plasma volume (PV) equations were applied as follows: 1) body surface area (BSA)-based equation: the estimated body surface area (BSA) (m^2^) was calculated as follows: (body weight)^0.425^ × (height)^0.72^ × 0.2025 \[[@R13]\]. The BSA-based PV (L) was calculated as BSA × 1.670 \[[@R14]\]. 2) Hematocrit (HCT)-based PV (L) was calculated as 0.07 × weight (kg) × (1 - HCT) \[[@R15]\]. The CEA amount (μg), representing the total amount of CEA within the circulation, was calculated as serum CEA concentration × estimated PV. Both CEA amount estimated by BSA and HCT were calculated. To determine the cut-off value of CEA amount, receiver operating characteristics (ROC) curve of CEA amount was analyzed, and cancer death was predicted by comparing the area under the curve. We decided the best cut-off value for BSA-based CEA amount was 12.09 (sensitivity: 78.65%; specificity: 50.0%; area under the ROC curve: 0.679) and HCT-based CEA amount was 10.52 (sensitivity: 77.58%; specificity: 52.0%; area under the ROC curve: 0.669).

Cumulative survival curves after surgery were calculated using the Kaplan-Meier method and differences were evaluated using the log-rank test. We used Wilcoxon rank-sum tests to assess associations between BMI and PV, serum CEA concentration and CEA amount, with P-values computed using the normal approximation. All statistical analyses were performed using JMP (SAS Institute Inc., Cary, NC, USA).

Results {#s3}
=======

The clinicopathological factors of patients based on BMI group were shown in [Table 1](#T1){ref-type="table"}. Among these NSCLC patients, 15.5% were categorized as low BMI, 57% as normal BMI, and 27.5% as high BMI. Age, gender, smoking status, pStage, pT status, pN status, and serum CEA concentration were not different between BMI groups. However, high BMI group had a statistically significant association with increasing adenocarcinoma histology (P = 0.016).

###### Clinical Characteristics of Patients Based on BMI

                     Low BMI   Normal BMI   High BMI   Total   P value
  ------------------ --------- ------------ ---------- ------- ---------
  Age                                                          
    ≤ 65             19        68           37         124     0.070
    \> 65            40        149          68         257     
  Gender                                                       
    Male             32        120          44         196     0.668
    Female           27        97           61         185     
  Smoking status                                               
    Never            26        94           51         171     0.577
    Current/former   33        123          54         210     
  Histology                                                    
    Adenocarcinoma   42        161          91         294     0.016
    Others           17        56           14         87      
  pStage                                                       
    I                42        169          84         295     0.433
    II-III           17        48           21         86      
  pT status                                                    
    pT1              33        153          71         257     0.114
    pT2-3            26        64           34         124     
  pN status                                                    
    pN0              51        182          92         325     0.645
    pN1-2            8         35           13         56      
  CEA                                                          
    Normal           39        160          80         279     0.375
    High             20        57           25         102     

CEA: carcinoembryonic antigen; BMI: body mass index.

As shown in [Table 2](#T2){ref-type="table"}, the BSA-based PV was significantly increased with higher BMI (P \< 0.001). Similarly, the HCT-based PV was also significantly associated with higher BMI (P \< 0.001). However, there was no association between serum CEA concentration and BMI (P = 0.171). We could not find even the trend towards an association between increasing BMI and decreasing CEA.

###### Plasma Volume, Serum CEA Concentration and CEA Amount Based on BMI

                            Low BMI       Normal BMI    High BMI      P value
  ------------------------- ------------- ------------- ------------- ----------
  BSA-based PV              2.3 ± 0.2     2.5 ± 0.2     2.7 ± 0.3     \< 0.001
  HCT-based PV              1.8 ± 0.3     2.3 ± 0.3     2.7 ± 0.4     \< 0.001
  Serum CEA concentration   28.1 ± 3.7    12.2 ± 0.8    15.5 ± 1.5    0.171
  BSA-based CEA amount      25.5 ± 64.8   15.1 ± 31.6   15.4 ± 41.8   0.842
  HCT-based CEA amount      20.1 ± 52.5   13.6 ± 29.2   15.1 ± 41.1   0.598

All values are expressed as mean ± standard deviation. BMI: body mass index; BSA: body surface area; HCT: hematocrit; PV: plasma volume; CEA: carcinoembryonic antigen.

The BSA-based CEA amount had no association with BMI (P = 0.842). The HCT-based CEA amount was not also significantly associated with increasing BMI (P = 0.598).

The survival of patients with preoperative high serum CEA concentration was significantly poorer than those with preoperative normal serum CEA (P \< 0.001; [Fig. 1a](#F1){ref-type="fig"}). Similarly, NSCLC patients with high CEA amount had a significantly worse survival than those with low CEA amount (P \< 0.001; [Fig. 1b, c](#F1){ref-type="fig"}). As shown in [Figure 1](#F1){ref-type="fig"}, the result of BSA-based CEA amount was consistent with that of HCT-based CEA amount. Both CEA amount could not provide any useful information in addition to serum CEA concentration.

![Survival of patients according to serum CEA concentration (a), BSA-based CEA amount (b) and HCT-based CEA amount (c).](wjon-08-041-g001){#F1}

Discussion {#s4}
==========

We demonstrated that high BMI patients had higher PV, in agreement with the results of previous investigations \[[@R04]\]. It was also previously demonstrated that the serum PSA concentration in obese individuals was lower compared with normal-weight individuals \[[@R04]\]. The hemodilution may therefore be a most considerable reason for the lower serum PSA concentrations among obese men with prostate cancer \[[@R04]\]. Compared with theses previous investigations, we failed to find no association between serum CEA concentration and BMI in NSCLC patients. In agreement with our results, some investigations also found no significant association between BMI and PSA \[[@R07], [@R08]\]. The reason for this discrepancy is unknown. Some possible reasons for this might be as follows. First, the present study represents a retrospective surgical cohort from a single institution. The characteristics of resected NSCLC patients may not reflect the all staged NSCLC patients and/or general population. Second, the present study is the first investigation for NSCLC. There are no previous investigations that showed the relationship between BMI and serum CEA concentration in NSCLC. Third, in the present study, the number of extremely obese Japanese patients is small. The patients with BMI \> 27.5 and \> 30 were only 5.0% (19/381) and 1.3% (5/381) of our study population, respectively. Yoshiike et al \[[@R16]\] reported that the standardized prevalence of obesity (BMI ≥ 30.0) in Japanese adults was quite low compared with the data in western populations. Therefore, because of small number of obese patients, there is a possibility that we might fail to find a hemodilution of CEA in Japanese NSCLC patients.

We found a statistical significant association between high BMI and higher PV, but not found the association between high BMI and serum CEA concentration. Therefore, it is easy to understand that increasing BMI is associated with increasing CEA amount. However, our result showed that there was no association between BMI and CEA amount in NSCLC patients. Therefore, the power of the obesity-related CEA hemodilution in NSCLC patients might be weak, and the hemodilution effect in the obese NSCLC patients might be clinically negligible.

Previous investigations showed the prognostic significance of serum CEA concentration in NSCLC \[[@R01]\]. If the power of the hemodilution effect in the obese NSCLC patients is strong, the prognostic significance of CEA amount might be more useful than that of serum CEA concentration. However, we could not find any differences between the survival curve based on serum CEA concentration and that based on CEA amount. Taken together, there might be no need to adjust the preoperative serum CEA concentration in relation to the BMI when used to predict the prognostic assessment in NSCLC patients.

The main limitations of our study are that all patients were surgery patients and the number of patients was small. Therefore, a large cohort study will be required to confirm our results.

Conclusions {#s4a}
-----------

In conclusions, we failed to find the association between BMI and CEA, suggesting the hemodilution effect in the obese NSCLC patients might be clinically negligible. Furthermore, the measurement of the CEA amount could not provide any additional information. Therefore, we believe that there is no need to adjust the preoperative serum CEA concentration in relation to the BMI in NSCLC patients.
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